# Getein Biotechnology

Getein Biotechnology is a Corporate Investor based in Nanjing, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Nanjing, China
- **Region:** Asia
- **Address:** No. 9 Bofu Road, Intelligent Manufacturing Industrial Park, Jiangbei New Area, Nanjing, Jiangsu 211505, China
- **Founded:** 2002
- **Assets under management:** Undisclosed
- **Website:** www.bio-gp.com.cn
- **LinkedIn:** https://www.linkedin.com/company/getein-biotechnology-co-ltd

## Regulatory record

- **Reports private funds:** No

## About

Getein Biotechnology launched in 2002 as a developer and manufacturer of in-vitro diagnostic products, growing from its Nanjing headquarters into a publicly traded entity on the Shanghai Stock Exchange by 2017. Founder Su Enben remains Chairman and CEO, holding approximately 39.77% of the company, which gives its corporate venture and investment activities a concentrated, founder-led decision-making structure unusual among listed Chinese healthcare firms. The wealth that fuels its investing comes directly from operating revenues in diagnostics — a sector that saw sustained demand growth in China over the past two decades. Getein deploys capital primarily through direct equity investments and strategic partnerships, targeting developers of diagnostic reagents, point-of-care testing devices, and medical instruments that complement its core manufacturing business. The firm's investment posture blends venture-stage exposure to emerging diagnostic platforms with control or near-control positions in companies that can integrate into its production and distribution infrastructure. The firm operates its headquarters and industrial base from an intelligent manufacturing park in Nanjing's Jiangbei New Area, signaling a commitment to vertically integrated production. While total deployment figures are not publicly disclosed, Getein's balance-sheet capacity is tied to its listed equity value and the recurring cash flows of its diagnostics sales. No separate venture fund vehicle or external limited-partner capital has been publicly identified, reinforcing the corporate-venture structure. The firm does not appear to maintain a philanthropic foundation or club-investment participation that is publicly documented. What structurally distinguishes Getein from generic corporate venture arms is the combination of founder control, public-market accountability, and a balance sheet entirely funded by operating profits in a single industrial vertical. It invests not to generate standalone financial returns but to extend the diagnostic manufacturing platform Su Enben built over two decades — making its investment decisions inseparable from product-roadmap and supply-chain logic.

## Sectors

- Digital Health
- Healthcare Services

## People

- Su Enben — Founder, Chairman, and CEO
- Catherine Xu — Director of International Trade Department
- Raymond Xu — Director of International Trade Department

## Questions

### Does Getein participate in fund commitments or only direct deals?

Based on public disclosures, Getein executes direct equity investments and strategic partnerships rather than committing to third-party funds. No limited-partner positions in external venture or private equity funds have been publicly identified. This direct-only posture keeps its capital tightly aligned with its own diagnostic manufacturing and distribution interests.

### How is Getein related to its Shanghai Stock Exchange listing?

Getein Biotechnology has been a publicly traded company since 2017, giving it access to equity capital markets alongside its operating cash flows. Founder Su Enben's roughly 39.77% stake means public shareholders participate alongside founder interests in the company's overall value creation, though investment decisions remain under founder control. The listing provides liquidity and transparency obligations atypical for private corporate-investment vehicles.

## Related profiles

- [Gestion Jean-Paul Auclair](https://altss.com/profile/gestion-jean-paul-auclair)
- [GF Holdings](https://altss.com/profile/gf-holdings)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/getein-biotechnology

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology